Ethical and Organisational considerations in screening for dementia

The United Kingdom National Screening Committee (UKNSC) defines screening as "the process of identifying individuals who may be at higher risk of a disease or condition amongst large populations of healthy people". Building on foundations laid by Wilson and Jungner in the landmark paper in 1968, the UKNSC states that "Once identified, those individuals can consider further tests, and healthcare providers can offer them interventions of benefit. A screening programme needs to offer more benefit than harm, at a reasonable cost to the NHS" (gov.uk 2014). We will consider the ethical issues surrounding some of the UK's screening programmes and other methods used to assess and communicate patients' risk of disease. We will discuss the appropriateness of candidate dementia biomarkers in order to inform research into developing such a biomarker or series of biomarkers.